PB1768: IS NATIVE E-COLI OR PEG-ASPERAGINASE FORMULATION A HIGHER RISK FOR VTE DEVELOPMENT IN PATIENTS WITH POST TREATMENT ACUTE LYMPHOBLASTIC LEUKEMIA? A META-ANALYSIS by J. T. Seki, E. Atenafu, H. Sibai

Get full text

P1020: SCREENING FOR PORTAL HYPERTENSION IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS by M. Davidson, F. Wong, M. Atri, H. Sibai, D. Maze, V. Cheung, T. Nye, J. Callum, E. Atenafu, V. Gupta

Get full text

P352: SYMPTOMATIC VTE INCIDENCE IN ADULT ALL TREATED WITH PEG-ASPARAGINASE COMPARED TO THE NATIVE L-ASPARAGINASE IN WITH AN ASPARAGINASE-BASED PROTOCOL by R. Chen, J. Seki, L. Liu, E. Atenafu, K. Yee, A. Schuh, V. Gupta, S. Chan, A. Schimmer, D. Maze, M. Minden, H. Sibai

Get full text

S158: FINAL RESULT OF TKI DISCONTINUATION TRIAL WITH DASATINIB FOR SECOND ATTEMPT OF TREATMENT FREE REMISSION AFTER FAILING FIRST ATTEMPT WITH IMATINIB: TREATMENT-FREE REMISSION AC... by D. Kim, E. Atenafu, D. Forrest, I. Bence-Bruckler, L. Savoie, M.-M. Keating, L. Busque, R. Delage, A. Xenocostas, E. Liew, P. Laneuville, K. Paulson, T. Stockley, J. Lipton, B. Leber

Get full text